Heptares partners with cubist to research new medicines targeting GPcrs

10-Jan-2013 - United Kingdom

Heptares Therapeutics announced they have signed an agreement with Cubist Pharmaceuticals, Inc. to collaborate on the research and discovery of new medicines targeting G protein-coupled receptors (GPCRs), which are membrane proteins involved in a broad range of biological processes and diseases.

Under the terms of the agreement, Cubist will receive exclusive worldwide rights to research, develop and commercialize products generated from the collaboration. The collaborative research will focus on up to two GPCR drug targets to be selected by Cubist. For the first target, Heptares will receive $5.5 million (USD) upfront and up to approximately $4 million in research funding plus milestones and royalties. Cubist also has the option to nominate a second GPCR target at a later point in the collaboration, which Heptares has agreed to work on according to pre-determined financials.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances